product summary
Loading...
company name :
MyBioSource
product type :
antibody
product name :
E Cadherin
catalog :
MBS540273
quantity :
0.1-0.15 ml WB Contr
price :
290 USD
clonality :
polyclonal
host :
rabbit
conjugate :
nonconjugated
reactivity :
human
application :
western blot, immunoprecipitation
more info or order :
product information
catalog number :
MBS540273
products type :
Antibody
products full name :
E Cadherin
products short name :
E Cadherin
other names :
E-cadherin; Cadherin-1; cadherin-1; CAM 120/80; E-Cadherin; uvomorulin; cell-CAM 120/80; epithelial cadherin; cadherin 1, E-cadherin (epithelial); calcium-dependent adhesion protein, epithelial; cadherin 1, type 1, E-cadherin (epithelial); CAM 120/80; Epithelial cadherin; E-cadherin; Uvomorulin
other gene names :
CDH1; CDH1; UVO; CDHE; ECAD; LCAM; Arc-1; CD324; CDHE; UVO; E-cadherin
uniprot entry name :
CADH1_HUMAN
clonality :
Polyclonal
host :
Rabbit
purity :
Affinity purifed
concentration :
~0.5mg/ml
storage stability :
Shipped at 4 degree C. Store at -20 degree C
tested application :
Western Blot (WB), Immunoprecipitation (IP)
other info1 :
Immunogen: peptide
other info2 :
Preservatives: 0.02% Na3N. Buffer: PO4-buffer/Tris/Glycine, pH 7.4-7.8. PO4-buffer/Tris/Glycine, pH 7.4-7.8
ncbi gi num :
31073
ncbi acc num :
CAA78353
uniprot acc num :
P12830
ncbi mol weight :
97,456 Da
ncbi pathways :
Adaptive Immune System Pathway 366160!!Adherens Junction Pathway 83070!!Adherens Junction Pathway 481!!Adherens Junctions Interactions Pathway 119533!!Apoptosis Pathway 105648!!Apoptotic Cleavage Of Cell Adhesion Proteins Pathway 105680!!Apoptotic Cleavage Of Cellular Proteins Pathway 105678!!Apoptotic Execution Phase Pathway 105677!!Arf6 Trafficking Events Pathway 137954!!Bacterial Invasion Of Epithelial Cells Pathway 149807
ncbi summary :
This gene is a classical cadherin from the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. Identified transcript variants arise from mutation at consensus splice sites. [provided by RefSeq, Jul 2008]
uniprot summary :
Function: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7. Ref.25E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta precursors. Has a strong inhibitory effect on APP C99 and C83 production. Ref.25. Subunit structure: Homodimer; disulfide-linked. Component of an E-cadherin/ catenin adhesion complex composed of at least E-cadherin/CDH1, beta-catenin/CTNNB1 or gamma-catenin/JUP, and potentially alpha-catenin/CTNNA1; the complex is located to adherens junctions. The stable association of CTNNA1 is controversial as CTNNA1 was shown not to bind to F-actin when assembled in the complex. Alternatively, the CTNNA1-containing complex may be linked to F-actin by other proteins such as LIMA1. Interaction with PSEN1, cleaves CDH1 resulting in the disassociation of cadherin-based adherens junctions (CAJs). Interacts with AJAP1, CTNND1 and DLGAP5 . By similarity. Interacts with TBC1D2. Interacts with LIMA1. Interacts with CAV1. Interacts with the TRPV4 and CTNNB1 complex . By similarity. Interacts with PIP5K1C. Interacts with RAB8B . By similarity. Interacts with DDR1; this stabilizes CDH1 at the cell surface and inhibits its internalization. Ref.10 Ref.17 Ref.19 Ref.20 Ref.21 Ref.22 Ref.23 Ref.28 Ref.30 Ref.31. Subcellular location: Cell junction. Cell membrane; Single-pass type I membrane protein. Endosome. Golgi apparatus trans-Golgi network. Note: Colocalizes with DLGAP5 at sites of cell-cell contact in intestinal epithelial cells. Anchored to actin microfilaments through association with alpha-, beta- and gamma-catenin. Sequential proteolysis induced by apoptosis or calcium influx, results in translocation from sites of cell-cell contact to the cytoplasm. Colocalizes with RAB11A endosomes during its transport from the Golgi apparatus to the plasma membrane. Ref.4 Ref.21 Ref.24 Ref.31. Tissue specificity: Non-neural epithelial tissues. Induction: Expression is repressed by MACROD1. Ref.26. Domain: Three calcium ions are usually bound at the interface of each cadherin domain and rigidify the connections, imparting a strong curvature to the full-length ectodomain. Ref.16. Post-translational modification: During apoptosis or with calcium influx, cleaved by a membrane-bound metalloproteinase (ADAM10), PS1/gamma-secretase and caspase-3 to produce fragments of about 38 kDa (E-CAD/CTF1), 33 kDa (E-CAD/CTF2) and 29 kDa (E-CAD/CTF3), respectively. Processing by the metalloproteinase, induced by calcium influx, causes disruption of cell-cell adhesion and the subsequent release of beta-catenin into the cytoplasm. The residual membrane-tethered cleavage product is rapidly degraded via an intracellular proteolytic pathway. Cleavage by caspase-3 releases the cytoplasmic tail resulting in disintegration of the actin microfilament system. The gamma-secretase-mediated cleavage promotes disassembly of adherens junctions. Ref.4 Ref.15 Ref.18N-glycosylation at Asn-637 is essential for expression, folding and trafficking.Ubiquitinated by a SCF complex containing SKP2, which requires prior phosphorylation by CK1/CSNK1A1. Ubiquitinated by CBLL1/HAKAI, requires prior phosphorylation at Tyr-754. Ref.33 Ref.34. Involvement in disease: Hereditary diffuse gastric cancer (HDGC) [MIM:137215]: A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body.Note: The disease is caused by mutations affecting the gene represented in this entry. Heterozygous germline mutations CDH1 are responsible for familial cases of diffuse gastric cancer. Somatic mutations has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer. Ref.46 Ref.51Endometrial cancer (ENDMC) [MIM:608089]: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.Note: Disease susceptibility is associated with variations affecting the gene represented in this entry.Ovarian cancer (OC) [MIM:167000]: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Sequence similarities: Contains 5 cadherin domains. Sequence caution: The sequence AAA61259.1 differs from that shown. Reason: Frameshift at positions 16, 22, 25, 28, 31, 34, 52, 67, 73, 76, 94, 102, 633 and 636.
size :
0.1-0.15 ml WB Control
price :
290 USD
more info or order :
company information
MyBioSource
P.O. Box 153308
San Diego, CA 92195-3308
sales@mybiosource.com
https://www.mybiosource.com
1-888-627-0165
headquarters: USA
MyBioSource, LLC was orginally founded in Vancouver by three enthusiastic scientists who are passionate about providing the world with the best reagents available. Together, they form a company with a big vision known as MyBioSource. MyBioSource is now located in San Diego, California, USA.

"MyBioSource's number 1 vision is to be the world's number 1 quality reagents provider."

Our goal is to provide researchers, scientists and customers alike with a one-stop-shop for all of their reagents needs, whether it is monoclonal antibody, polyclonal antibody, recombinant protein, peptide, etc...

"MyBioSource offers the best products at unbeatable prices."

Please spend a few minutes to browse our online catalogs and see the wide range of products available. We ship our products through our shipping/distribution facility in San Diego, California, USA.

Would you like to receive email and e-newsletter from MyBioSource about new products, special offers and events? Please click here to join our Mailing List!